Injectable Bacitracin’s Lone Indication Should Be Revoked, US FDA Panel Says

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
An advisory committee said the benefit/risk profile for bacitracin injection's use in pediatric pneumonia is not positive.

More from US FDA Performance Tracker

More from Regulatory Trackers